Skye Bioscience, Inc. SKYE

Annual Quarterly

No quarterly revenue total was found in Skye Bioscience, Inc.'s SEC filings.

Skye Bioscience, Inc. (SKYE) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$7.1 million. As of Jun 30, 2026 it held $10.1 million in cash and investments and $35,696 in total debt.

Revenue
—
Net income
$-10.79M
+38.8% vs year-ago quarter
Operating cash flow
$-7.12M
+33.7% vs year-ago quarter
Free cash flow
$-7.12M
+33.7% vs year-ago quarter
EPS
$-0.27
+38.6% vs year-ago quarter
Dividend per share
None
Shares outstanding
35.42M
+14.3% vs year-ago quarter
Net cash
$10.03M
Q2 FY2026
Operating margin
—

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
SKYE (Nasdaq)
Fiscal year ends
December 31
Incorporated in
NV
Headquarters
San Diego, CA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1516551
Former names
Emerald Bioscience, Inc. (until Jan 7, 2021); Nemus Bioscience, Inc. (until Mar 14, 2019); LOAD GUARD LOGISTICS, INC. (until Oct 30, 2014); LOAD GUARD TRANSPORTATION, INC. (until Nov 7, 2012)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Key figures

Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.

Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Q4 FY2025
Dec 31, 2025
Q3 FY2025
Sep 30, 2025
Q2 FY2025
Jun 30, 2025
Operating income
-$11.1M
-$12.7M
-$14.9M
-$13.3M
-$18.2M
Net income
-$10.8M
-$12.5M
-$14.4M
-$12.8M
-$17.6M
Diluted EPS
-$0.27
-$0.32
-$0.36
-$0.32
-$0.44
Operating cash flow
-$7.1M
-$8.6M
-$9.8M
-$13.4M
-$10.7M
Free cash flow
-$7.1M
-$8.6M
-$9.8M
-$13.4M
-$10.7M
Total assets
$11.0M
$19.4M
$28.3M
$41.3M
$52.2M
Total liabilities
$11.5M
$10.4M
$8.3M
$8.5M
$8.5M
Stockholders' equity
-$497,307
$9.0M
$20.0M
$32.8M
$43.7M
Cash and investments
$10.1M
$17.1M
$25.7M
$35.3M
$48.6M
Total debt
$35,696
$60,980
$273,646
$321,845
$367,540

Recent SEC filings

Form Description Filed Period
8-K Current report
Agreement ended, Officer or director change, Other events
 Sep 11, 2026 Sep 8, 2026
8-K Current report
Material agreement, Unregistered share sale
 Aug 24, 2026 Aug 21, 2026
8-K/A Amended current report
Change to shareholder rights
 Aug 20, 2026 Aug 12, 2026
8-K Current report
Listing notice
 Aug 19, 2026 Aug 18, 2026
10-Q Quarterly report Aug 14, 2026 Jun 30, 2026
8-K Current report
Material agreement, Unregistered share sale, Change to shareholder rights, Change in control, Officer or director change, Bylaw or fiscal year change, Regulation FD disclosure
 Aug 14, 2026 Aug 12, 2026

All 631 Skye Bioscience, Inc. SEC filings

Source: SEC EDGAR filings. This is company-reported data, not investment advice.